PMV Pharmaceuticals (PMVP) Accumulated Expenses (2019 - 2026)

PMV Pharmaceuticals (PMVP) has 8 years of Accumulated Expenses data on file, last reported at $6.7 million in Q1 2026.

• Quarterly Accumulated Expenses rose 140.22% year-over-year to $6.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.7 million (up 140.22% YoY) and the FY2025 annual result came in at $7.9 million, up 5.62% from the prior year.
• Accumulated Expenses declined to $6.7 million in Q1 2026, from $7.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $10.3 million in Q3 2024 to a low of $2.2 million in Q1 2024.
• A 5-year average of $6.0 million and a median of $6.7 million in 2026 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 261.8% — and 2024, when it plunged 73.99%.
• Tracing PMVP's Accumulated Expenses over 5 years: stood at $7.3 million in 2022, then slumped by 38.45% to $4.5 million in 2023, then jumped by 65.38% to $7.4 million in 2024, then advanced by 5.62% to $7.9 million in 2025, then decreased by 15.09% to $6.7 million in 2026.
• The last three Accumulated Expenses figures came in at $6.7 million (Q1 2026), $7.9 million (Q4 2025), and $8.5 million (Q3 2025), per Business Quant data.